References
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29
- Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract 2011;65:1180-92
- Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371:424-33
- Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368:138-48
- National Comprehensive Cancer Network, Pennsylvania, USA 2014. NCCN Guideline Prostate Cancer. 2014. http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed August 10, 2016
- Food and Drug Administration Maryland, USA, 2016. Xtandi [package insert]. 2015. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/203415s007lbl.pdf. Accessed October 21, 2015
- Food and Drug Administration, Maryland, USA 2016. Zytiga [package insert]. 2015. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/202379s016lbl.pdf. Accessed December 10, 2015
- Pilon D, Queener M, Lefebvre P, et al. Cost per median overall survival month associated with abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer. J Med Econ 2016; 19:777-84
- Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988;318:1728-33
- Belozeroff V, Lee A, Tseng S, et al. Cost per responder analysis in patients with secondary hyperparathyroidism on dialysis treated with cinacalcet. J Med Econ 2013;16:1154-62
- Bria E, Cuppone F, Giannarelli D, et al. Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?: meta-analysis of randomized trials. Cancer 2009;115:3446-56
- Liu Y, Wu EQ, Bensimon AG, et al. Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis. Adv Ther 2012;29:620-34
- Martin S, Feldman SR, Augustin M, et al. Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis. J Dermatolog Treat 2011;22:138-43
- Schmitz-Dräger BJ, Weiss C, Ebert T, et al. Skeletal-related events in metastatic prostate cancer and the number needed to treat: a critical consideration. Urol Int 2013;90:329-33
- Wu EQ, Xie J, Signorovitch J, et al. Number needed to treat and treatment cost per fracture avoided with denosumab compared with zoledronic acid in patients with breast cancer with bone metastases. J Clin Oncol 2011;29:abstr 151
- Xie J, Diener M, Wu E, et al. Number needed to treat and risk benefit analysis of denosumab versus zoledronic acid in the treatment of castrate-resistant prostate cancer patients with bone metastasis. J Urol 2012;187:e74
- Rathkopf DE, Smith MR, de Bono JS, et al. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol 2014;66:815-25
- National Institute for Health and Care Excellence, London, UK. NICE publishes draft guidance on two prostate cancer treatments. 2015. www.nice.org.uk/news/press-and-media/nice-publishes-draft-guidance-on-two-prostate-cancer-treatments. Accessed January 5, 2016
- Truven Health Analytics, London, UK. Red Book Online. 2016. http://www.redbook.com/redbook/. Accessed March 15, 2016
- Centers for Medicare and Medicaid Services, Maryland, USA. Medicare Physician Fee Schedule. 2015. http://www.cms.gov/apps/physician-fee-schedule/search/search-criteria.aspx. Accessed January 4, 2016
- Centers for Medicare and Medicaid Services, Maryland, USA. Clinical diagnostic laboratory fee schedule for Medicare. 2015. http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/clinlab.html. Accessed January 4, 2016
- Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015;16:152-60
- Adigopula S, Babu V, Parperis KM, et al. Hyperglycemia in heart failure patients is associated with increased length of stay and costs. Circulation 2009;120:S548
- Agency for Healthcare Research and Quality, Maryland, USA. HCUP Nationwide Inpatient Sample. 2013. https://www.hcup-us.ahrq.gov/db/nation/nis/nisdbdocumentation.jsp. Accessed January 4, 2016
- Borker R. Costs associated with adverse events in patients with metastatic renal cell carcinoma. J Med Econ 2014;17:792-97
- Fu az, Zhao Z, Wang S, et al. Hospital costs of adverse events in patients with metastatic colorectal cancer. J Cancer Ther 2013;4:153-8
- Hagiwara M, Borker R, Oster G. Economic burden of adverse events in patients with metastatic renal cell carcinoma. Clin Ther 2013;35:1955-63
- Ivanova JI, Birnbaum HG, Kidolezi Y, et al. Direct and indirect costs associated with epileptic partial onset seizures among the privately insured in the United States. Epilepsia 2010;51:838-44
- Lage MJ, Barber BL, Harrison DJ, et al. The cost of treating skeletal-related events in patients with prostate cancer. Am J Manag Care 2008;14:317-22
- Wu EQ, Birnbaum HG, Mareva M, et al. Economic burden and co-morbidities of atrial fibrillation in a privately insured population. Curr Med Res Opin 2005;21:1693-9
- Food and Drug Administration, Maryland, USA. Provenge product label 2014. 2016. http://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM210031.pdf. Accessed May 14, 2015
- Food and Drug Administration, Maryland, USA. Docetaxel [package insert]. 2016. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022234s03lbl.pdf. Accessed May 28, 2015
- Food and Drug Administration, Maryland, USA. Jevtana [package insert] 2014. 2016. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/201023s011lbl.pdf. Accessed August 24, 2015
- United States Department of Labor, Washington DC, USA. Bureau of Labor Statistics: The Consumer Price Index. 2014. http://www.bls.gov/cpi/. Accessed January 5, 2016
- Muennig P, Bounthavong M. Cost-effectiveness analysis in health: a practical approach, 3rd edn. San Francisco, CA: Jossey-Bass, 2016
- Ellis LA, Lafeuille MH, Gozalo L, et al. Treatment sequences and pharmacy costs of 2 new therapies for metastatic castration-resistant prostate cancer. Am Health Drug Benefits 2015;8:185-95
- Stevens JA, Corso PS, Finkelstein EA, et al. The costs of fatal and non-fatal falls among older adults. Inj Prev 2006;12:290-5
- Schuetz P, Balk R, Briel M, et al. Economic evaluation of procalcitonin-guided antibiotic therapy in acute respiratory infections: a US health system perspective. Clin Chem Lab Med 2015;53:583-92
- Verbraecken J, Van de Heyning P, De Backer W, et al. Body surface area in normal-weight, overweight, and obese adults. A comparison study. Metabolism 2006;55:515-24
- Bergman J, Saigal CS, Lorenz KA, et al. Hospice use and high-intensity care in men dying of prostate cancer. Arch Intern Med 2011;171:204-10
- Centers for Medicare and Medicaid Services, Maryland, USA. Health Care Information System (HCIS) Data File. HCIS Data Files for 2011. 2011. https://www.cms.gov/Research-Statistics-Data-and-Systems/Files-for-Order/NonIdentifiableDataFiles/HealthCareInformationSystem.html. Accessed January 4, 2016